JP2021523114A5 - - Google Patents
Info
- Publication number
- JP2021523114A5 JP2021523114A5 JP2020561635A JP2020561635A JP2021523114A5 JP 2021523114 A5 JP2021523114 A5 JP 2021523114A5 JP 2020561635 A JP2020561635 A JP 2020561635A JP 2020561635 A JP2020561635 A JP 2020561635A JP 2021523114 A5 JP2021523114 A5 JP 2021523114A5
- Authority
- JP
- Japan
- Prior art keywords
- lymphoma
- celduratinib
- cocrystal
- solvate
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024001279A JP2024024093A (ja) | 2018-05-04 | 2024-01-09 | リンパ腫の治療方法 |
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862667249P | 2018-05-04 | 2018-05-04 | |
| US62/667,249 | 2018-05-04 | ||
| US201862678934P | 2018-05-31 | 2018-05-31 | |
| US62/678,934 | 2018-05-31 | ||
| US201862736047P | 2018-09-25 | 2018-09-25 | |
| US62/736,047 | 2018-09-25 | ||
| PCT/US2019/030690 WO2019213589A1 (en) | 2018-05-04 | 2019-05-03 | Methods for treating lymphoma |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024001279A Division JP2024024093A (ja) | 2018-05-04 | 2024-01-09 | リンパ腫の治療方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021523114A JP2021523114A (ja) | 2021-09-02 |
| JP2021523114A5 true JP2021523114A5 (https=) | 2022-05-18 |
Family
ID=66554509
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020561635A Pending JP2021523114A (ja) | 2018-05-04 | 2019-05-03 | リンパ腫の治療方法 |
| JP2024001279A Pending JP2024024093A (ja) | 2018-05-04 | 2024-01-09 | リンパ腫の治療方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024001279A Pending JP2024024093A (ja) | 2018-05-04 | 2024-01-09 | リンパ腫の治療方法 |
Country Status (11)
| Country | Link |
|---|---|
| US (3) | US11266645B2 (https=) |
| EP (1) | EP3787628A1 (https=) |
| JP (2) | JP2021523114A (https=) |
| KR (1) | KR20210003789A (https=) |
| CN (1) | CN112074271B (https=) |
| AU (1) | AU2019262644A1 (https=) |
| BR (1) | BR112020022430A2 (https=) |
| CA (1) | CA3098012A1 (https=) |
| MX (1) | MX2020011817A (https=) |
| TW (1) | TW202014190A (https=) |
| WO (1) | WO2019213589A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019213606A2 (en) | 2018-05-04 | 2019-11-07 | Portola Pharmaceuticals, Inc. | Solid forms of cerdulatinib |
| TWI805751B (zh) | 2018-05-04 | 2023-06-21 | 美商普托拉製藥有限公司 | 賽度替尼(cerdulatinib)之合成 |
| US20250032499A1 (en) * | 2021-11-22 | 2025-01-30 | Secura Bio, Inc. | Methods of treating peripheral t-cell lymphoma |
| CN114306606B (zh) * | 2021-11-29 | 2023-05-26 | 江苏省人民医院（南京医科大学第一附属医院） | cGAS抑制剂在制备治疗T细胞淋巴瘤的药物中的应用 |
| CN115177620A (zh) * | 2022-07-18 | 2022-10-14 | 厦门大学附属第一医院 | 西奥罗尼或其药学上可接受的盐在制备预防或治疗滤泡淋巴瘤的药物中的应用 |
| WO2024115935A1 (en) * | 2022-11-29 | 2024-06-06 | Inserm | Methods for the treatment of b-cell lymphoma using cd39 inhibitors |
| CN117427166B (zh) * | 2023-09-25 | 2024-09-10 | 中山大学肿瘤防治中心（中山大学附属肿瘤医院、中山大学肿瘤研究所） | Csf1r抑制剂用于制备nk/t细胞淋巴瘤治疗药物的应用 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT1974747E (pt) * | 1998-08-11 | 2012-09-05 | Biogen Idec Inc | Terapias de combinação para linfomas de células b compreendendo a administração de anticorpo anti-cd20 |
| WO2006086103A2 (en) | 2005-01-10 | 2006-08-17 | University Of Virginia Patent Foundation | Synthesis of inhibitors of p90rsk |
| US8138339B2 (en) | 2008-04-16 | 2012-03-20 | Portola Pharmaceuticals, Inc. | Inhibitors of protein kinases |
| WO2015081127A2 (en) * | 2013-11-26 | 2015-06-04 | Gilead Sciences, Inc. | Therapies for treating myeloproliferative disorders |
| JP7258462B2 (ja) * | 2015-05-29 | 2023-04-17 | ポートラ ファーマシューティカルズ， エルエルシー | Ｂ細胞悪性腫瘍の治療のためのセルデュラチニブ |
| US10736895B2 (en) * | 2015-12-04 | 2020-08-11 | Portola Pharmaceuticals, Inc. | Cerdulatinib for treating hematological cancers |
-
2019
- 2019-05-03 CA CA3098012A patent/CA3098012A1/en active Pending
- 2019-05-03 JP JP2020561635A patent/JP2021523114A/ja active Pending
- 2019-05-03 CN CN201980029463.1A patent/CN112074271B/zh active Active
- 2019-05-03 MX MX2020011817A patent/MX2020011817A/es unknown
- 2019-05-03 BR BR112020022430-8A patent/BR112020022430A2/pt not_active Application Discontinuation
- 2019-05-03 KR KR1020207032288A patent/KR20210003789A/ko not_active Withdrawn
- 2019-05-03 AU AU2019262644A patent/AU2019262644A1/en not_active Abandoned
- 2019-05-03 WO PCT/US2019/030690 patent/WO2019213589A1/en not_active Ceased
- 2019-05-03 EP EP19724683.8A patent/EP3787628A1/en not_active Withdrawn
- 2019-05-03 US US16/403,227 patent/US11266645B2/en active Active
- 2019-05-03 TW TW108115469A patent/TW202014190A/zh unknown
-
2022
- 2022-01-31 US US17/589,562 patent/US20220233533A1/en not_active Abandoned
-
2024
- 2024-01-09 JP JP2024001279A patent/JP2024024093A/ja active Pending
-
2025
- 2025-02-01 US US19/043,427 patent/US20250213562A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021523114A5 (https=) | ||
| EP4110338A1 (en) | A triple pharmaceutical combination comprising dabrafenib, an erk inhibitor and a shp2 inhibitor | |
| Fenelon et al. | Efficacy and tolerability of entacapone in patients with Parkinson's disease treated with levodopa plus a dopamine agonist and experiencing wearing-off motor fluctuations. A randomized, double-blind, multicentre study | |
| RU2015120616A (ru) | Лечение злокачественных опухолей с использованием модуляторов изоформ pi3-киназы | |
| US20040029869A1 (en) | Methods and compositions for treating or preventing sleep disturbances and associated illnesses using very low doses of cyclobenzaprine | |
| US8492383B2 (en) | Combination of a nitrogen mustard analogue and imatinib for treatment of chronic lymphocytic leukemia | |
| EP3010505A1 (en) | Pharmaceutical combinations | |
| JP2018520117A5 (https=) | ||
| JP2022116304A (ja) | 血液がんの治療のためのＰＰＡＲγアゴニスト | |
| PT2177223E (pt) | Tratamento da leucemia mielóide crónica, resistente ou intolerante ao sti571, envolvendo a homoharringtonina isoladamente ou em combinação com outros agentes | |
| WO2022090443A1 (en) | Administration and dose regimen for a combination of a bcl-2 inhibitor and a mcl1 inhibitor | |
| JP2021522246A (ja) | 癌治療のための併用 | |
| IL292882A (en) | Dosage of Bruton's tyrosine kinase inhibitor | |
| EP3664787B1 (en) | Use of selective serotonin 5-ht1a receptor agonists for treating side-effects of vmat inhibitors | |
| JP2006508118A5 (https=) | ||
| JP2025529240A5 (https=) | ||
| JP2024517788A (ja) | Ｍｐｎｓｔの処置のための化合物及び組成物 | |
| Freerksen et al. | Malaria therapy and prophylaxis with cotrifazid, a multiple complex combination consisting of rifampicin+ isoniazid+ sulfamethoxazole+ trimethoprim | |
| AU2022254484A1 (en) | Combinations of lsd1 inhibitors for treating myeloid cancers | |
| RU2020137882A (ru) | Способы лечения лимфомы | |
| Florea et al. | Focus on... Voriconazole A novel azole antifungal. | |
| EP3130339B1 (en) | A compound for use in the treatment of comorbid anxiety disorder and depression disorder | |
| CN101282728A (zh) | 有机化合物的组合 | |
| KR950703958A (ko) | Hiv 감염증을 치료하기 위한,다른 비뉴클레오사이드 역 전사효소 억제제와 혼합된 bhap 화합물의 용도(use of bhap compounds in combination with other non-nucleoside reverse transcriptase inhibitors for the treatment of hiv infection) | |
| WO1995020388A1 (en) | Anti-hiv drugs |